BrightPath Biotherapeutics
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Phase 2
Terminated
- Conditions
- Metastatic NSCLC
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03417882
- Locations
- 🇺🇸
St Joseph Hospital of Orange, Orange, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Florida Hosptial Cancer Center- AdventHealth, Orlando, Florida, United States
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02696356
- Locations
- 🇺🇸
The Christ Hospital Cancer Research, Cincinnati, Ohio, United States
🇺🇸Providence Health and Services, Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸University of Pittsburg, Pittsburgh, Pennsylvania, United States
News
No news found